Advertisement

Topics

Cofactor Genomics Partners with FLX Bio for Immuno-Oncology Analysis Platform

17:38 EST 1 Dec 2016 | Biotech-Finances

Thursday, December 1st 2016 at 3:00pm UTC SAN FRANCISCO–(BUSINESS WIRE)– Cofactor Genomics, a leader in a new class of RNA products for disease research and diagnostics, announced today that they have partnered with FLX Bio, a biopharmaceutical company focused on the discovery and development of novel immuno-oncology (IO) therapeutics, to develop a novel RNA-based IO …

Cet article Cofactor Genomics Partners with FLX Bio for Immuno-Oncology Analysis
Platform
est apparu en premier sur EEI-BIOTECHFINANCES.

Original Article: Cofactor Genomics Partners with FLX Bio for Immuno-Oncology Analysis Platform

NEXT ARTICLE

More From BioPortfolio on "Cofactor Genomics Partners with FLX Bio for Immuno-Oncology Analysis Platform"

Quick Search
Advertisement
 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...